BATON ROUGE, LA-(September 21, 2016) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) (“OncBioMune” or the “Company”), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, today announces the release of a patient testimonial video by prostate cancer survivor Stephen Karalekas. The video tells the story of Mr. Karalekas and his experience with the OncBioMune team and the Company’s experimental immunotherapy prostate cancer vaccine, ProscaVax.

Mr. Karalekas earned degrees at the United States Naval Academy, Harvard University and Indiana University before serving on the White House staff of President Richard Nixon and Capitol Hill as Chief of Staff for a Congressman from Massachusetts. Following that, he spent the rest of his time in Washington, D.C. as an attorney and lobbyist.

Diagnosed with prostate cancer in March 2005, Mr. Karalekas underwent a radical prostatectomy and then, through a friend in Washington, D.C., was introduced to OncBioMune and ProscaVax. He subsequently began ProscaVax therapy in 2006. In the words of Mr. Karalekas, “low and behold, about six months later, my PSA had disappeared.” PSA is an acronym for “prostate specific antigen,” a commonly used measure of prostate cancer. Mr. Karalekas goes on to say that when the results of his PSA tests were obtained at the National Cancer Institute, the doctors were shocked, as they expected to see the progression of his disease marked by a continuing rise in his PSA.

To this day, Mr. Karalekas still receives a ProscaVax booster shot every six months.

“I am happy to say that 11 years later, I’m sitting before you in excellent health, no side effects, no issues, no problems and I’m in perfect health,” says Mr. Karalekas. “The doctors at the National Cancer Institute and, subsequently, at Mass General in Boston…say that there is nothing to be done, you’ll live a happy, normal, healthy existence.”

“I would not like to finish this interview without expressing my profound gratitude and appreciation for OncBioMune, Dr. Jonathan Head and Dr. Robert Elliott for the work that they’re doing for mankind and the work that they did for me,” concluded Mr. Karalekas.

The video is available for viewing at:

ProscaVax is an experimental immunotherapy vaccine being developed for the treatment of prostate cancer. ProscaVax is currently being evaluated in a Phase 1 clinical study at the University of California San Diego Moores Cancer Center and Veterans Hospital in La Jolla, California, funded in part by the Department of Defense US Navy Cancer Vaccine Program. A Phase 2/3 trial of ProscaVax is expected to commence enrollment in the near future in Mexico through a Joint Venture with Vitel Laboratorios, S.A. de C.V. evaluating ProscaVax for the treatment of PSA recurrent prostate cancer in hormone-naïve and hormone-independent patients. A Phase 2 trial is also planned to be initiated this year at Beth Israel Deaconess Medical Center and partners to evaluate ProscaVax in prostate cancer patients in the “active surveillance” category. Readers are cautioned that while promising data on ProscaVax has been produced, there are no assurances that ProscaVax will complete the regulatory pathway to receive FDA clearance for marketing to the public or that Mr. Karalekas’ results are typical or indicative of future clinical outcomes.

Sign up for OncBioMune email alerts at:

About OncBioMune Pharmaceuticals, Inc.

OncBioMune Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a proprietary Vaccine Technology that is designed to stimulate the immune system to attack its own cancer while not hurting the patient. Our lead product, ProscaVax® is scheduled to commence a Phase 2 clinical study in 2016. OncBioMune also has a portfolio of targeted therapies, some of which are biosimilars to blockbuster drugs. OncBioMune is headquartered in Baton Rouge, LA.

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor there be any sale of these securities in any jurisdiction in which such offer solicitation or sale are unlawful prior to registration or qualification under securities laws of any such jurisdiction.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause OncBioMune Pharmaceuticals’ actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. OncBioMune Pharmaceuticals has in some cases identified forward-looking statements by using words such as “anticipates,” “believes,” “hopes,” “estimates,” “looks,” “expects,” “plans,” “intends,” “goal,” “potential,” “may,” “suggest,” and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are OncBioMune Pharmaceuticals’ need for, and the availability of, substantial capital in the future to fund its operations and research and development; the fact that OncBioMune Pharmaceutical’s vaccines and therapeutics may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in OncBioMune Pharmaceutical’s filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. OncBioMune Pharmaceuticals undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.


OncBioMune Pharmaceuticals, Inc.
Andrew Kucharchuk
President and Chief Financial Officer
[email protected]